Evidence map›Paper›PMID 28806732›Full record

ArticlePLoS genetics2017

Loss of the chromatin modifier Kdm2aa causes BrafV600E-independent spontaneous melanoma in zebrafish.

Catherine M Scahill, Zsofia Digby, Ian M Sealy, Sonia Wojciechowska, Richard J White, John E Collins, Derek L Stemple, Till Bartke, Marie E Mathers, E Elizabeth Patton and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Catherine M ScahillWellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Zsofia DigbyWellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Ian M SealyWellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.ORCID http://orcid.org/0000-0002-2890-6635
Sonia WojciechowskaMRC Institute of Genetics and Molecular Medicine, MRC Human Genetics Unit & The University of Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, United Kingdom.
Richard J WhiteWellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.ORCID http://orcid.org/0000-0003-1842-412X
John E CollinsWellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Derek L StempleWellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
Till BartkeMRC London Institute of Medical Sciences (LMS), London, United Kingdom.ORCID http://orcid.org/0000-0002-6584-2140
Marie E MathersDepartment of Pathology, Western General Hospital, Edinburgh, United Kingdom.
E Elizabeth PattonMRC Institute of Genetics and Molecular Medicine, MRC Human Genetics Unit & The University of Edinburgh Cancer Research UK Centre, University of Edinburgh, Edinburgh, United Kingdom.
Elisabeth M Busch-NentwichWellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.ORCID http://orcid.org/0000-0001-6450-744X
Wellcome Sanger Institute · GBEdinburgh Cancer Research · GBHelmholtz Zentrum München · DEUniversity of Cambridge · GBWestern General Hospital · GB

Funding

Identifying genes required for digestive physiology and lipid metabolismR01DK093399 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI STEVEN A FARBER, John F Rawls · 2013 to 2026
$7.6M
European Research Council 309952Medical Research Council MC_PC_U127585840Medical Research Council MC_UP_1102/2NIDDK NIH HHS R01 DK093399Wellcome Trust
6 · The paper itself

Abstract

KDM2A is a histone demethylase associated with transcriptional silencing, however very little is known about its in vivo role in development and disease. Here we demonstrate that loss of the orthologue kdm2aa in zebrafish causes widespread transcriptional disruption and leads to spontaneous melanomas at a high frequency. Fish homozygous for two independent premature stop codon alleles show reduced growth and survival, a strong male sex bias, and homozygous females exhibit a progressive oogenesis defect. kdm2aa mutant fish also develop melanomas from early adulthood onwards which are independent from mutations in braf and other common oncogenes and tumour suppressors as revealed by deep whole exome sequencing. In addition to effects on translation and DNA replication gene expression, high-replicate RNA-seq in morphologically normal individuals demonstrates a stable regulatory response of epigenetic modifiers and the specific de-repression of a group of zinc finger genes residing in constitutive heterochromatin. Together our data reveal a complex role for Kdm2aa in regulating normal mRNA levels and carcinogenesis. These findings establish kdm2aa mutants as the first single gene knockout model of melanoma biology.

Indexed as

AnimalsDisease Models, AnimalDNA ReplicationEpigenesis, GeneticExomeFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockout TechniquesJumonji Domain-Containing Histone DemethylasesMaleMelanomaMutationProto-Oncogene Proteins B-rafRNA, MessengerSequence Analysis, RNAJumonji Domain-Containing Histone DemethylasesProto-Oncogene Proteins B-rafRNA, MessengerZebrafish Proteins

Identifiers

PMID28806732
PMCPMC5570503
OpenAlexW2748066657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.